Updated
Viral infection
Shiitake, agarikon, turkey tail and six others have been tried in people for this. The register's own words for this are influenza, herpes, HIV, COVID-19.
Thirteen registered trials have looked at this, and 5 of them reported.
Species by species
| Species | How far it has got | Trials | With a result | Randomised | Commonly taken for it |
|---|---|---|---|---|---|
| Shiitake Lentinula edodes | Repeated trials | 3 | 0 | 2 | — |
| Agarikon Fomitopsis officinalis | Repeated trials | 2 | 2 | 1 | yes |
| Turkey tail Trametes versicolor | Repeated trials | 2 | 2 | 1 | — |
| Antrodia Taiwanofungus camphoratus | A first trial | 1 | 1 | 0 | — |
| Button mushroom Agaricus bisporus | A first trial | 1 | 0 | 1 | — |
| Poria Wolfiporia extensa | A first trial | 1 | 0 | 1 | — |
| Oyster mushroom Pleurotus ostreatus | Being tested now | 1 | 0 | 0 | — |
| Reishi Ganoderma lucidum | Being tested now | 1 | 0 | 0 | — |
| Zhu ling Polyporus umbellatus | Being tested now | 1 | 0 | 0 | — |
The trials themselves
Every registered study that names one of these species and a condition the register files under this heading.
| Register | Study | Condition | People | Status | Result posted | Dose in the protocol |
|---|---|---|---|---|---|---|
| NCT04523181 | Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized | Covid-19 | 124 | Completed | yes | — |
| NCT04951336 | RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination | COVID-19 Vaccination | 90 | Completed | yes | — |
| NCT04951336 | RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination | COVID-19 Vaccination | 90 | Completed | yes | — |
| NCT04667247 | RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19 | COVID-19 | 54 | Completed | yes | 8 capsule |
| NCT04667247 | RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19 | COVID-19 | 54 | Completed | yes | 8 capsule |
| NCT04846010 | Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 | Sequelae of; Infection, Post Infection Glomerulonephritis | 2000 | Unknown | — | — |
| NCT04846010 | Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2 | Sequelae of; Infection, Post Infection Glomerulonephritis | 2000 | Unknown | — | — |
| NCT06739720 | RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue | Chronic Fatigue Syndrome (CFS), Post-COVID ME/CFS | 130 | Recruiting | — | — |
| NCT06041867 | Agaricus Bisporus and Influenza Vaccination Response | Immune Response | 88 | Completed | — | 10 capsule, 500 mg |
| NCT04646980 | Biobran/MGN-3 Increases Innate Resistance and Reduces the Incidence of Influenza-like Illnesses | Influenza-like Illness | 80 | Completed | — | 500 mg |
| NCT00002098 | Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and L | HIV Infections | 50 | Completed | — | — |
| NCT00069524 | Antihyperlipidemic Effects of Oyster Mushrooms | HIV Infections, Hyperlipidemia | 20 | Completed | — | — |
| NCT00002099 | Phase II/III Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and | HIV Infections | — | Unknown | — | — |
Memory and focusMood and anxietySleepFatigue and energyImmune functionCancer, supportive and adjuvantBlood sugarCholesterol and lipidsGut and microbiomeExercise performanceInflammationLiverSkinLungs and breathingKidneyNerve repairAllergyMouth and gumsLibido and fertilityBlood and clottingBacterial infectionWound healingFluid retentionNutrition